Braveheart Bio, Inc. has priced its initial public offering at $18.00 per share for a total of 21,250,000 shares of common stock, the company announced in a press release. At the stated price, the offering is projected to produce gross proceeds of $382.5 million prior to the deduction of underwriting discounts, commissions, and other expenses.
The underwriting group has been granted a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price, should the underwriters elect to exercise that option. Shares were expected to begin trading on the Nasdaq Global Market on August 6, 2026. The offering was expected to close on August 7, 2026, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are acting as joint book-running managers for the transaction. These firms will handle the institutional and retail placement processes associated with the IPO and any exercise of the underwriters option.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on therapies for cardiovascular disease. The company is headquartered in San Francisco. Its lead investigational candidate, BHB-1893, is described by the company as an oral small-molecule cardiac myosin inhibitor. The candidate is being developed for the treatment of both obstructive and non-obstructive hypertrophic cardiomyopathy.
The company and its underwriters outlined the timetable for the offering and the potential additional share issuance through the option, and made clear that the closing remains subject to customary conditions that typically accompany public offerings. No additional changes to the size, structure, or pricing beyond those disclosed were announced in the release.
Context and next steps
The planned Nasdaq listing and the exercise period for the underwriters option set the framework for potential additional supply of shares within 30 days after the offering. Market participants will observe the initial trading of BRVE on Nasdaq beginning August 6, 2026, and follow the formal closing expected on August 7, 2026, assuming customary closing conditions are satisfied.